X
NVO

Xponance’s Novo Nordisk NVO Stock Holding History

Xponance’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
6,335
+563
+10% +$24.2K ﹤0.01% 1395
2026
Q1 		$212K Buy
5,772
+1,424
+33% +$67.5K ﹤0.01% 1447
2025
Q4 		$221K Buy
4,348
+457
+12% +$23.4K ﹤0.01% 1340
2025
Q3 		$216K Buy
3,891
+519
+15% +$30.4K ﹤0.01% 1331
2025
Q2 		$233K Buy
3,372
+58
+2% +$3.94K ﹤0.01% 1258
2025
Q1 		$230K Buy
3,314
+158
+5% +$13.1K ﹤0.01% 1217
2024
Q4 		$271K Buy
3,156
+146
+5% +$15.8K ﹤0.01% 1164
2024
Q3 		$358K Buy
3,010
+345
+13% +$46K ﹤0.01% 1036
2024
Q2 		$380K Buy
2,665
+576
+28% +$76.3K ﹤0.01% 986
2024
Q1 		$268K Buy
2,089
+32
+2% +$3.81K ﹤0.01% 1094
2023
Q4 		$213K Sell
2,057
-671
-25% -$66.4K ﹤0.01% 1142
2023
Q3 		$248K Buy
+2,728
New +$240K ﹤0.01% 1078

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Xponance's NVO Position: Q2 2026 in Review

Xponance increased its Novo Nordisk (NVO) stake by 9.8% in Q2 2026, buying an estimated $24.2K and bringing the position to 6,335 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

Xponance first reported a position in NVO in Q3 2023 and has held it in 12 quarters since. The position peaked at $380K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Xponance held 6,335 shares of Novo Nordisk worth $304K as of Q2 2026.
  • Xponance bought 563 Novo Nordisk shares in Q2 2026, an estimated $24.2K.
  • Novo Nordisk made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1395 holding.
  • Xponance first reported a position in Novo Nordisk in Q3 2023 and has held it in 12 quarters since.
  • Xponance's Novo Nordisk position peaked at $380K in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.